While 2 years is the maximum duration of clinical trials on Semaglutide GLP-1, the length of treatment may be shorter or longer depending on individual circumstances
Liraglutide, injectable semaglutide, and dulaglutide have shown statistically significant reductions in major adverse cardiovascular events in patients with established cardiovascular disease or multiple risk factors
Animal models show intestinal protection from GLP-1 receptor agonists
"It's not any different than hypertension or diabetes or the many other chronic illnesses that we deal with, where you have to use chronic medication." For over the past three years, the arrival of a new class of drugs known as GLP-1 agonists, so-called for their ability to mimic the action of the natural GLP-1 gut hormone that promotes satiety, has transformed the weight-loss field
More research is needed into the effects of individual nutrients, specific foods, and dietary patterns in humans
Distribution and properties of glucagon immunoreactivity in the digestive tract of various mammals: an immunohistochemical and immunochemical study